Korro Bio, Inc. Forecasted to Earn Q3 2024 Earnings of ($2.79) Per Share (NASDAQ:KRRO)

Korro Bio, Inc. (NASDAQ:KRRO) – Research analysts at William Blair issued their Q3 2024 earnings per share estimates for Korro Bio in a research note issued on Monday, September 16th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($2.79) for the quarter. William Blair has a “Outperform” rating and a $180.00 price objective on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($10.29) per share. William Blair also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.89) EPS, FY2024 earnings at ($10.56) EPS, Q1 2025 earnings at ($2.95) EPS, Q2 2025 earnings at ($2.99) EPS, Q3 2025 earnings at ($3.04) EPS, Q4 2025 earnings at ($3.09) EPS and FY2025 earnings at ($12.07) EPS.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.04).

Several other analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Korro Bio in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $95.00 target price on shares of Korro Bio in a report on Thursday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $135.00.

Korro Bio Stock Down 5.6 %

Shares of Korro Bio stock opened at $36.33 on Thursday. Korro Bio has a twelve month low of $9.15 and a twelve month high of $97.91. The firm’s 50-day moving average price is $43.48 and its 200 day moving average price is $51.22.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds have recently modified their holdings of the company. Atlas Venture Life Science Advisors LLC purchased a new position in Korro Bio in the fourth quarter worth approximately $53,648,000. Monashee Investment Management LLC acquired a new stake in shares of Korro Bio during the 4th quarter worth about $4,352,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the fourth quarter valued at about $13,269,000. Eventide Asset Management LLC purchased a new position in Korro Bio during the fourth quarter worth about $26,185,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Korro Bio in the 2nd quarter valued at approximately $649,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).